|

RYZ101 Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • RayzeBio, Inc.2

Indications

  • Cancer2
  • Pancreatic NET1
  • Carcinoid1
  • Gastroenteropancreatic Neuroendocrine Tumor Disease1
  • GEP-NET1

Phoenix, Arizona2 trials

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Research Facility

Phase 3
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Research Facility

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.